NOD Related Publications

Atkinson MA1, Leiter EH. (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med. 5(6):601-4.

Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL. (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest. 118(4):1532-43.

Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, Mayer A, Czerkinsky C, Holmgren J, Thivolet C. (1997) A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA. 94(9):4610-4.

Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. (2004) Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest. 114(7):979-87.

da Costa SR, Wu K, Veigh MM, Pidgeon M, Ding C, Schechter JE, Hamm-Alvarez SF. (2005) Male NOD mouse external lacrimal glands exhibit profound changes in the exocytotic pathway early in postnatal development. Exp Eye Res. 82(1):33-45.

Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. (2006) Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest. 116(8):2252-61.

Gordon EJ, Wicker LS, Peterson LB, Serreze DV, Markees TG, Shultz LD, Rossini AA, Greiner DL, Mordes JP. (2005) Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. Diabetes. 54(1):107-15.

Goudy K, Song S, Wasserfall C, Zhang YC, Kapturczak M, Muir A, Powers M, Scott-Jorgensen M, Campbell-Thompson M, Crawford JM, Ellis TM, Flotte TR, Atkinson MA. (2001) Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA. 98(24):13913-8.

Homo-Delarche F. (2004) Neuroendocrine immuno-ontogeny of the pathogenesis of autoimmune disease in the nonobese diabetic (NOD) mouse. ILAR J. 45(3):237-58.

Irie J, Wu Y, Kachapati K, Mittler RS, Ridgway WM. (2007) Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes. 56(1):186-96.

Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, Finkelman FD, Eisenbarth GS. (2002) Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest. 110(7):1021-7.

Mabley JG, Rabinovitch A, Suarez-Pinzon W, Haskó G, Pacher P, Power R, Southan G, Salzman A, Szabó C. (2003) Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol Med. 9(3-4):96-104.

Ryu S, Kodama S, Ryu K, Schoenfeld DA, Faustman DL. (2001) Reversal of established autoimmune diabetes by restoration of endogenous β cell function. J Clin Invest. 108(1):63-72.

Swyers J. (2007) Antibody therapy prevents type 1 diabetes in mice. EurekAlert.

Tian C, Bagley J, Cretin N, Seth N, Wucherpfennig KW, Iacomini J. (2004) Prevention of type 1 diabetes by gene therapy. J Clin Invest. 114(7):969-78.

Tracy S, Drescher KM, Chapman NM, Kim KS, Carson SD, Pirruccello S, Lane PH, Romero JR, Leser JS. (2002) Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J Virol. 76(23):12097-111.

Washburn LR, Dang H, Tian J, Kaufman DL. (2007) The postnatal maternal environment influences diabetes development in nonobese diabetic mice. J Autoimmun. 28(1):19-23.